Sort
39,280 grants matching “leukemia”
Therapeutic Targeting of Human AML Stem Cells
$931,335Craig T. Jordan · University Of Colorado Denver · R35 · FY2021 · CA
Molecular pathways and targeted therapies in human leukemia
$931,200Adolfo A. Ferrando · Columbia University Health Sciences · R35 · FY2019 · CA
T-cell Transformation by Oncoviruses
$930,803Genoveffa Franchini · Division Of Basic Sciences - Nci · Z01 · FY2008 · CA
An allosteric inhibitor of ZAP-70 as a novel therapeutic for autoimmune disease
$930,793Arthur Weiss · University Of California, San Francisco · RC2 · FY2009 · AR
Retrovirus Assembly and Maturation
$930,640Alan Rein · Division Of Basic Sciences - Nci · ZIA · FY2009 · CA
University of Pennsylvania Patient-derived Xenograft Development and Trials Center
$930,590Martin Carroll · University Of Pennsylvania · U54 · FY2023 · CA
Human natural killer cells: Advancing biology and clinical applications
$930,000Michael A Caligiuri · Ohio State University · R35 · FY2017 · CA
CALGB STUDIES OF BREAST CANCER IN THE ELDERLY
$929,517University Of Chicago · U10 · FY2001 · CA
Novel signaling molecules regulating platelet activation
$928,728Satya P. Kunapuli · Temple Univ Of The Commonwealth · R35 · FY2023 · HL
Pathophysiology of HTLV-I and HTLV-II Infection
$928,670Edward L Murphy · University Of California, San Francisco · R01 · FY2008 · HL
Preclinical Development of JS-K, a Novel NO-Generating Prodrug for Cancer
$927,566Sudhir Sahasrabudhe · Jsk Therapeutics, Inc. · R44 · FY2012 · CA
Investigating the heterogeneity and coordination of hematopoietic stem cells
$927,429Rong Lu · University Of Southern California · R35 · FY2024 · HL
Pathophysiology of HTLV-I and HTLV-II Infection
$925,969Edward L Murphy · University Of California, San Francisco · R01 · FY2006 · HL
First-in-class ETS inhibitor TK216: Translational Biology and Oral Dosage Form Development
$925,560Gunnar Joerg Floris Kaufmann · Oncternal Therapeutics, Inc. · R44 · FY2021 · CA
Characterization of brain dysfunction during development in survivors of childhood acute lymphoblastic leukemia
$925,510Elyse S Sussman · Albert Einstein College Of Medicine · R01 · FY2023 · CA
Molecular pathogenesis and therapy innovation for Merkel cell carcinoma
$925,055Isaac Brownell · National Institute Of Arthritis And Musculoskeletal And Skin Diseases · ZIA · FY2022 · AR
Molecular-Cellular Regulation of Hematopoietic Stem Cells
$924,901Jonathan R Keller · Division Of Basic Sciences - Nci · ZIA · FY2020 · CA
Microfluidic CAR-T Cell Processing Device
$924,383Tony Ward · Gpb Scientific, Inc. · R42 · FY2019 · CA
Drug candidates that disrupt the NEMO/IKK signaling complex for the treatment of
$924,148Stig K. Hansen · Carmot Therapeutics, Inc. · R44 · FY2014 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2018 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2016 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2017 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2020 · CA
Cancer Gene Discovery to Identify Targetable Targets
$924,000Carlo M Croce · Ohio State University · R35 · FY2015 · CA
Manipulation of Immune Responsiveness after Hematopoietic Cell Transplantation
$924,000Robert Jon Soiffer · Dana-Farber Cancer Inst · R01 · FY2014 · CA